BDSX Overview

Biodesix, Inc. is a diagnostic solutions company. The Company's business includes Biodesix Lung Diagnostic Testing and Biodesix Development Services. Its Biodesix Lung Diagnostic Testing provides lung diagnostic testing services for healthcare providers through five blood-based tests. Its Biodesix Development Services supports global biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that enable the development of diagnostic tests, tools, and therapeutics. The Company offers Nodify Lung tests and IQLung tests that assess cancer risk and provide treatment guidance following a lung cancer diagnosis. The Nodify Lung tests include Nodify CDT and Nodify XL2 tests, which evaluate the risk of lung cancer in lung nodules. The GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests are used in the diagnosis of lung cancer to detect tumor mutations and assess the patient’s immune system status.

Wall Street analysts forecast BDSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDSX is30.00 USD with a low forecast of 20.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Biodesix Inc revenue for the last quarter amounts to 25.55M USD, increased 42.30

Biodesix Inc. EPS for the last quarter amounts to -0.81 USD, decreased -46.36

Biodesix Inc (BDSX) has 334 emplpoyees as of June 20 2026.

Today BDSX has the market capitalization of 174.08M USD.